Further analyses from the Phase 1/1b CHRYSALIS-2 study showed patients with osimertinib pre-treated EGFR-mutated lung…
– Phase 2 Mechanism of Action Trial Results Demonstrate the Immunomodulatory Effects of Trilaciclib in…
CHICAGO–(BUSINESS WIRE)–#biomarker—Nucleai, a leading provider of artificial intelligence (AI) solutions for pathology and spatial biology,…
The clinical trial of the personalized cancer vaccine EVX-01 met its primary endpoints of safety…
Additional long-term data from the TRiMM-2 study in patients receiving talquetamab and DARZALEX® (daratumumab) subcutaneous (SC)…
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data…
BEERSE, BELGIUM, June 03, 2023 (GLOBE NEWSWIRE) — The Janssen Pharmaceutical Companies of Johnson &…
– Data presented at ASCO annual meeting demonstrate 55% Disease Control Rate (DCR) in heavily…
Updated data from ongoing IGNYTE anti-PD1 failed melanoma cohort shows RP1 combined with nivolumab continues…
– Met Primary Endpoint with 63.4% Median Reduction in LDL-C (p<0.0001) – – 87.1% of Patients Treated…
Enactment of Federal Legislation to Raise U.S. Debt Limit Ratifies and Expedites Approvals, Declares Project…
LOS ANGELES–(BUSINESS WIRE)–$S—Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm,…
Findings in over 3,000 subjects demonstrate highly sensitive and specific detection of multiple cancers at…
Data update from AFM24-101 phase 1/2 monotherapy study includes 15 patients from the EGFR mutant…
Long Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrate Potential of Allogeneic CD19…
ELI-002 was shown to be well-tolerated with no dose limiting toxicity or cytokine release syndrome…
– Marked increases in overall survival observed across soft tissue sarcoma patients – – Demonstrated…
Early on-treatment ctDNA reduction in stable disease patients treated with KIMMTRAK was associated with longer…
NEW YORK–(BUSINESS WIRE)–Massive Bio, a leader in leveraging artificial intelligence and concierge services to empower…
CHATHAM, ONTARIO and TEL-AVIV, ISRAEL, June 02, 2023 (GLOBE NEWSWIRE) — Atlas Global Brands Inc….